EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sensei Biotherapeutics's Enterprise Value is $-21.68 Mil.
Sensei Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-32.20 Mil. Therefore, Sensei Biotherapeutics's EV-to-FCF for today is 0.67.
The historical rank and industry rank for Sensei Biotherapeutics's EV-to-FCF or its related term are showing as below:
SNSE'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 2.93
Current: 0.67
During the past 6 years, the highest EV-to-FCF of Sensei Biotherapeutics was 2.93. The lowest was 0.00. And the median was 0.00.
SNSE's EV-to-FCF is ranked better than 71.28% of 390
companies
in the Biotechnology industry
Industry Median: 6.365
vs SNSE: 0.67
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sensei Biotherapeutics's EV-to-FCF
For the Biotechnology subindustry, Sensei Biotherapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sensei Biotherapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sensei Biotherapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sensei Biotherapeutics's EV-to-FCF falls into.
Sensei Biotherapeutics's current Enterprise Value is $-21.68 Mil.
Sensei Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-32.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Sensei Biotherapeutics's PE Ratio for today is calculated as:
Sensei Biotherapeutics's share price for today is $1.51.
Sensei Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.220.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sensei Biotherapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Sensei Biotherapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Sensei Biotherapeutics (Sensei Biotherapeutics) Business Description
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. The company currently has three investigational products. 1) SNS-101 is a conditionally active monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T-cell activation): 2) SNS-102 is a conditionally active monoclonal antibody targeting VSIG4 (V-Set and Immunoglobulin Domain Containing 4), an immune checkpoint often expressed on macrophages: 3) SNS-103 is a conditionally active monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1), also known as CD39.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SNSE has been successfully added to your 